2016 industry partnering summit

8/17/2019 2016 Industry Partnering Summit

1/16


2/16

http://unemed.com/http://unemed.com/


3/16

1

2016 INDUSTRY PARTNERING SUMMIT

UNeMed.com | 402.559.2468

SCHEDULE OF EVENTSMay 10, 2016 | Linder Reading Room, Michael F. Sorrell Center, UNMC | Omaha, Nebraska

9 a.m. Opening Remarks

Overview: UNMC Pharmaceutical Research

Technology & Start-up Presentations

Lunch & Networking

9:10 a.m. Dept. of Pharmacology & Experimental Neuroscience — Howard Gendelman, M.D.

9:25 a.m. Dept. of Cellular & Integrative Physiology — Irving Zucker, Ph.D.

9:40 a.m. Dept. of Pathology & Microbiology — Steven Hinrichs, M.D.

9:55 a.m. Center for Drug Delivery and Nanomedicine — Joe Vetro, Ph.D.

10:10 a.m. Fred & Pamela Buffet Cancer Center — TBA

10:25 a.m. Break

10:35 a.m.Vaccine Strategy for Parkinson’s Disease:

Howard Gendelman, M.D.

10:50 a.m.

Potent small molecule antibacterial

compounds:

Rongshi Li, Ph.D.

11:05 a.m.

Glyoxalase-1 gene therapy for the treatment of

diabetes-related complications:

Keshore Bidasee, Ph.D.

11:20 a.m.

Inhibiting MDSCs for the

treatment of biofilm infections:

Tammy Kielian, Ph.D.

11:35 a.m.CCL21 nanoparticles for cancer immunotherapy:

Joyce Solheim, Ph.D.

1:10 p.m.IKK-beta inhibitors:

Amar Natarajan, Ph.D.

1:25 p.m.

Glucocorticoid prodrug for the improved

treatment of lupus:

Dong Wang, Ph.D.

1:40 p.m.Immune stimulating peptides:

Prommune, Inc.

1:55 p.m. Targeted radiopharmaceuticals:Calidum, Inc.

2:10 p.m.

Nanoformulations for the treatment of acute

spinal cord injury:

ProTransit Nanotherapy, LLC

2:30 p.m. Poster Session & Networking

Welcome toUNeMed’s2016 Industry

PartneringSummit


4/16


UNeMed.com | 402.559.2468

2

Vaccine Strategy forParkinson’s Disease

A group led by Howard Gendelman, M.D., atUNMC has developed a novel vaccine strategycapable o both preventing Parkinson’s Diseaseonset as well as preventing disease progression.

Te vaccine combines the immunogen, N-α-Syn, with a molecular adjuvant that is capableo promoting a regulatory adaptive immune re-sponse (regulatory cell response) such as vaso-active intestinal peptide or GM-CSF.

esting o the Parkinson’s vaccine strategywas carried out in a mouse model o Parkinson’sdisease. reatment using the novel vaccination strategy resulted in a

decrease in activatedmicroglia by 61 percentand a 64 percent decreasein neuronal injury.Furthermore, this vaccinestrategy prevented loss odopaminergic neuronsallowing or an astonishing91 percent survival rate or

dopaminergic neurons.Dr. Gendelman’s group

has recently completeda human study lookingat the effect o a poten-tial adjuvant (GM-CSF)to modulate the immuneprofile in Parkinson’s pa-tients. Administration oGM-CSF successully up-regulated the regulatory cell response providingadditional support or this vaccine strategy.

Prevents

futuredisease,treatsexisting

disease

UNMC Technology

Back


5/16

3


UNeMed.com | 402.559.2468

27 times morepotent thanvancomycin

against staph

Potent small molecule

antibacterial compounds

Researchers at the University o Nebraska aredeveloping a new class o small molecules or thetreatment o bacterial inections.

Tey have currently developed lead com-pounds with nano-molar MICs against staph and

anthrax. One o these compounds had a potencysimilar to ciprofloxacin against anthrax and was27-old more potent than vancomycin againststaph.

Some o these compounds also displayedbroad spectrum activity demonstrating low mi-cromolar MICs against some gram negative bac-teria such as A. baumannii, Enterobacter, and K.

pneumonia.Work is currently being done to urther eval-uate some o the lead compounds in vivo againststaph and anthrax.

New analogs are also being designed to im-prove activity against gram negative bacteria.

UNMC Technology

Back


6/16

4


UNeMed.com | 402.559.2468

Reactive carbonyl species areofen over-produced in diseases likediabetes, resulting in increases inoxidative stress, inflammation andDNA damage.

Methylglyoxal, or MGO, isthe most potent o these reactivecarbonyl species. It increases as earlyas three days afer hyperglycemia andcould be responsible or vascular/cardiovascular dysunction.

UNMC research Keshore Bidasee,Ph.D., and his group have developeda gene therapy to strategically

reduce MGO by overexpressesingglyoxalase-1, an enzyme that degradesMGO. Te gene therapy contains akey promoter region that expressesglyoxalase-1 only in damaged cellsthat are producing excess MGO.

When injected intravenously indiabetic animals, the viral constructimproved the unctions o the heartand brain, two key end-organsnegatively impacted in diabetes. Te

therapy also improved cognition andreduced stroke damage (cerebralischemia-reperusion injury), andalso modestly lowered blood glucose.

Glyoxalase-1 overexpression isa novel therapeutic approach orblunting cerebral vascular dysunctionand cognitive impairment in diabetes.Since microvascular dysunction is an

established cause or other diabeticcomplications—blindness, kidneyailure, diabetic cardiomyopathy,erectile dysunction and stroke—lowering MGO levels will alsodiminish these complications.

Gene therapy for the treatment

of diabetes-related complications

Improve

brain & heart

function in

diabetic

patients

UNMC Technology

Back

http://www.unemed.com/product/reduce-complications-diabeteshttp://www.unemed.com/product/reduce-complications-diabeteshttp://www.unemed.com/product/reduce-complications-diabetes


7/16

5


UNeMed.com | 402.559.2468

Inhibiting MDSCs for thetreatment of biofilm infections

Prevent,

treat anddestroybiofilms bytargeting

the immunesystem

ammy Kielian, Ph.D., has generated amethod to enhance the ability o a patients’immune system to eliminate bacterial biofilms.Tis method ocuses on the inhibition o speci-ic cell populations knows as myeloid-derived

suppressor cells, or MDSCs.In the presence o MDSCs, inflammation

persists but does not acilitate bacterial clear-ance. In addition, monocyte/macrophage infil-trates are reduced and cell prolieration andcytokine production are inhibited. Depletion oMDSCs enhances the proinflammatory proper-ties o infiltrating monocytes and macrophages

allowing or improved bacterial clearance.Dr. Kielian’s group is currently testing var-ious approaches to inhibit MDSC unction(such as SA3 inhibitors) to identiy potentialtherapeutic strategies or the treatment o bio-film inections.

UNMC Technology

Back

http://www.unemed.com/product/targeted-biofilm-preventionhttp://www.unemed.com/product/targeted-biofilm-preventionhttp://www.unemed.com/product/targeted-biofilm-prevention


8/16

6


UNeMed.com | 402.559.2468

CCL21 nanoparticles forcancer immunotherapy

Significant

inhibitionof tumorgrowth inanimal

studies

atiana Bronich, Ph.D., and JoyceSolheim, Ph.D., are developing thechemokine CCL21 as an immuno-therapy. Intratumoral administrationof CCL21 elicits a potent anti-tumorresponse through the recruitment ofimmune cells into the tumor, suchas dendritic cells, cells and naturalkiller cells.

However, one problem with thisapproach is that CCL21 doesn’t lastlong inside the body, and its effectsare short-lived.

o get around this, Drs. Bronichand Solheim created a nanoformula-tion that protects CCL21 from deg-radation and will allow for extendedrelease of CCL21 within the tumorsite, prolonging the chemotactic effect

and increasing the overall therapeuticimpact.

Release kinetics of the nanopar-ticles have been analyzed and op-timized. Te researchers have alsoperformed small scale animal studiesusing subcutaneous Pan02 tumorswhere the nanoformulated CCL21showed significant inhibition of tu-mor growth over nine days.

In addition to use as a standaloneimmunotherapy, the CCL21 nanopar-ticles can also enhance other immu-

notherapies.By enhancing immune infiltration

into tumors, the CCL21 nanoparticlescan greatly enhance the efficacy of tu-mor vaccines, cell therapies, oncolytic

viruses and antibody therapies.

UNMC Technology

Back

http://www.unemed.com/product/ccl21-immunotherapy-cancerhttp://www.unemed.com/product/ccl21-immunotherapy-cancerhttp://www.unemed.com/product/ccl21-immunotherapy-cancer


9/16

7


UNeMed.com | 402.559.2468

IKK-beta inhibitors

Researchers at UNMC have identified a set o compounds that act as in-hibitors o the NF-κB pathway and specifically inhibit IKKβ. Initial work hasocused on the lead compound called “13-197.”

“13-197” has been evaluated using a wide variety o in vitro assays anddemonstrated antiprolierative activity against apanel o cancer cell lines. It also inhibited NF-κB

Potentinhibitorof cancer cell

proliferation

mediated gene transcription, enhanced caspase3/7 activity, induced apoptosis, and sensitizedpancreatic cancer cells to gemcitabine.

“13-197” has been tested in two different

in vivo cancer models. In an orthotopic mousemodel o pancreatic cancer, “13-197” signifi-cantly decreased tumor size and tumor metas-tasis. “13-197” also decreased inflammation andmicrovessel density within the pancreatic tum-ors while increasing tumor necrosis.

“13-197”has also been tested in a mouse mod-el o mantle cell lymphoma where it reduced tu-mor burden in the kidney, liver and lungs, andsignificantly increased the overall survival o themice.

Researchers are now working on developingadditional analogs o “13-197,” and hope to ad- vance into the clinic soon.

UNMC Technology

Back

http://www.unemed.com/product/nfkb-pathway-inhibitorshttp://www.unemed.com/product/nfkb-pathway-inhibitors


10/16

8


UNeMed.com | 402.559.2468

Glucocorticoid prodrug for theimproved treatment of lupusA UNMC team led by Dong Wang,

Ph.D., has developed a promisingdrug candidate for the therapy of Lu-pus Nephritis, a kidney disease thataffects 30 percent to 60 percent of Sys-

temic Lupus Erythematosus patients.Te drug candidate is a prodrug of

a commonly prescribed treatment forLupus, a cortiocosteroid called gluco-corticoid. Cortiocosteroids are limit-ed in their ability to effectively treatLupus because they cause severe sys-temic side effects, including adrenalgland suppression, osteoporosis andimpaired liver function.

When modified with polyethyl-ene glycol (PEG), the glucocorticoidprodrug created by Dr. Wang’s teamspecifically targets inflamed kidney

tissue. Te modification essential-ly made it possible to eliminate theharmful side effects, and create a farmore effective long-term treatmentoption for lupus nephritis.

Animal studies showed the newprodrug compound, PEG-glucocor-ticoid, has a long-lasting effect, andthat monthly dosing had a betteroverall effect on established nephritisthan daily traditional treatments. Tetests also showed that the monthlyPEG-glucocorticoid treatment in-creased lifespan and reduced inci-dence of severe kidney disease. Tenew treatment also did not affectbone quality, the peripheral whiteblood cell count or suppress the ad-renal gland.

UNMC Technology

Longer-lastingand moreeff ective thantraditional

dailytreatments

Back


11/16

9


UNeMed.com | 402.559.2468

Immune stimulating peptidesPrommune’s lead immune simu-

latory peptide, EP67, selectively en-gages and activates antigen present-ing cells (monocytes, macrophages,dendritic cells) to induce the cellularand molecular elements associatedwith innate immunity—the body’sfirst line o immune deense against

inection.Once activated by EP67, these anti-

gen presenting cells are primed to takeup infective pathogens (bacteria, vi-ruses, fungi) and destroy them via nat-ural cellular mechanisms.

Tus, EP67 can be usedto awaken and direct thebody’s own innate im-mune responses againstinective pathogens—

Host-Directed Immune Terapy(HDI).

Importantly, the EP67-activatedcellular processes for HDI makeno distinction between normal orantibiotic-resistant pathogens. Tus,EP67-mediated HDI can be usedto fight normal as well as antibiot-

ic-resistant infections, and could beused as a complement to traditionalantibiotics to deliver a powerful dualtherapeutic assault on troublesomeinfections.

Prommune Inc.

is a research anddevelopment companythat has created aunique and patentedmeans to safely andeff ectively awaken the

body’s own naturalimmune defenseswithout inflammatoryside-eff ects

UNMC Startup

Back

http://prommuneinc.com/http://prommuneinc.com/


12/16

10


UNeMed.com | 402.559.2468

Targeted cancer therapyCalidum Inc. is developing compounds that

are tagged with a radioactive isotope that willhelp clinicians better diagnose, track and treat various cancers that include prostate, ovarian,and triple negative breast cancers, neuroblasto-ma and glioblastoma.

Calidum is developing radiopharmaceuticalsthat target the androgen receptor, butyrylcho-

linesterase and a third target.Due to the strong saety and activity data oCalidum’s lead compound, CDM-P123I, the U.S.Food and Drug Administration has approved aPhase-1 clinical trial in prostate cancer patients.

CDM-P123I specifically targets the andro-gen receptor on prostate cancer cells, thus it canboth identiy and effectively destroy those cellswith dramatically reduced side-effects and with higher specificity than current

techniques.Calidum will begin its Phase 1 trial or prostate cancer within the next 12

months, while completing the necessary preclinical studies to initiate humantrials or the additional targets in the next three years.

UNMC Startup

Calidum Inc.

is developingproducts based ona novel concept ofreceptor-targeted& DNA co-targeteddelivery of radiation

directly to the DNAof a cancer cell

Back

http://prommuneinc.com/http://prommuneinc.com/


13/16

11


UNeMed.com | 402.559.2468

Nanoformulations for

treating acute spinal cord injury

Nearly 1.3 million Americans, most othem young people, are living with pa-ralysis due to spinal cord injury, costing$40.5 billion or their annual care.

Te pathophysiology o traumatic spi-nal cord injury involves the initial physi-cal impact, which leads to secondary injury cascades o degenerative cellular andmolecular events. Te secondary injuryspreads along the spinal cord over time,which adds new levels o disability andhas devastating effects.

Proransit Nanotherapy is developingnanoormulated biotherapeutics to prevent the degenerative events that ollowsthe injury.

Called Pro-NP,™ the technology provedeffective in regaining locomotive unc-tions when used three hours afer injury.Pro-NP™ could potentially be adminis-tered in the field at the accident site o oren route to a health care acility.

UNMC Startup

ProTransit

Nanotherapy LLC isdeveloping therapiesbased on potentbiomacromoleculartherapueticsusing patented

nanoparticletechnology

Back

http://www.protransitnanotherapy.com/http://www.protransitnanotherapy.com/http://www.protransitnanotherapy.com/


14/16

12


UNeMed.com | 402.559.2468

Dept. of Pharmacology andExperimental NeuroscienceChair: Howard Gendelman, M.D.

Dept. Cellular andIntegrative PhysiologyChair: Irving Zucker, Ph.D.

Dept. of Pathology andMicrobiologyChair: Steven Hinrichs, M.D.

Center for Drug Deliveryand NanomedicineJoe Vetro, Ph.D.

Fred & PamelaBuff et Cancer CenterTBA

Department Overviews

CD74-based gene therapy forAlzheimer’s disease (Tomomi Kiyota, Ph.D.)

Development of subtype selectiveNMDA modulators (Dan Monaghan, Ph.D.)

New approaches for the diagnosis & treatment

of pancreatic cancer (Surinder Batra, Ph.D.)

Role of miR-133a in pathophysiology ofdiabetic hearts (Paras Kumar Mishra, Ph.D.)

Screen to identify genes that are essential

and selective for tumor cells (Rob Lewis, Ph.D.)

Antimicrobial peptides and UNMC’santimicrobial peptide database (Gus Wang, Ph.D.)

Pancreatic Diff erentiation Factor 2 a target for

the treatment of cancer (Surinder Batra, Ph.D.)

siRNA Delivery System (Joe Vetro, Ph.D.)

The role of the thromboxane receptor inobesity and diabetes(Saraswathi Viswanathan, Ph.D.)

Efficient insertion of sequences using longersingle stranded repair DNAswith CRISPR/Cas9 genome editing

(Channabasavaiah Gurumurthy, Ph.D.)

Cyclophilin D: A target for thetreatment of renal diseases and obesity(Babu Padanilam, Ph.D.)

Poster Titles

Back


15/16

http://unemed.com/http://unemed.com/


16/16

Transferring technology for UNMC since 1991

25TH ANNIVERSARY
http://unemed.com/http://unemed.com/http://bit.ly/UNeMedLinkhttp://bit.ly/UNePicshttp://bit.ly/UNeMedVideohttps://twitter.com/UNeMedhttp://facebook.com/UNeMedCorphttp://unemed.com/http://unemed.com/

2016 industry partnering summit

Documents